Plain-English translation of NCT07217938 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether pravastatin, a medication commonly used to manage cholesterol, can help improve swallowing difficulties that develop after radiation treatment for head and neck cancer. Swallowing problems can be a long-lasting side effect of radiation therapy, and researchers want to see if this medication might reduce scarring in the throat and make swallowing easier. You would take the medication daily for up to 12 months while doctors monitor your swallowing with tests.
Some people who receive radiation therapy for head and neck cancer develop lasting swallowing problems that can affect their quality of life and nutrition. There is currently no proven treatment for this complication, so researchers are exploring whether this medication's ability to reduce scarring might help improve swallowing function.
You likely qualify if…
You likely don't qualify if…
You would take one pravastatin tablet (40 mg) by mouth every day for up to 12 months. Before you start, during the treatment period, and after you finish, you'll have swallowing assessments—these involve drinking some liquid while doctors watch or use imaging to see how well you swallow. You'll also have blood tests to make sure the medication is safe for you. The trial is expected to recruit about 48 participants over 6 months.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Australia